This filing is strongly positive. Monitor the ASCO presentation for detailed data (hazard ratios, magnitude of benefit) and the PDUFA date (July 17, 2026) for potential approval. Consider accumulating ahead of these catalysts; any delay or negative committee review could introduce volatility.
Price Chart
Executive Summary
Celcuity announced positive topline Phase 3 VIKTORIA-1 results for gedatolisib in PIK3CA mutant HR+/HER2- advanced breast cancer, showing statistically significant PFS improvement vs alpelisib. The FDA has granted Priority Review for the NDA with a PDUFA date of July 17, 2026, and the company plans to file an sNDA. This is a major de-risking event for gedatolisib and Celcuity's lead asset.
Key Facts
- Positive Phase 3 VIKTORIA-1 results: gedatolisib triplet (gedatolisib + fulvestrant + palbociclib) showed statistically significant improvement in PFS vs alpelisib + fulvestrant in PIK3CA mutant HR+/HER2- advanced breast cancer.
- Gedatolisib doublet also showed statistically significant PFS improvement vs alpelisib + fulvestrant.
- FDA granted Priority Review for gedatolisib NDA in PIK3CA wild-type advanced breast cancer, with PDUFA goal date July 17, 2026.
- Celcuity plans to submit these data as a supplemental NDA to the FDA and to other regulatory authorities.
- Results to be presented as late-breaking oral abstract at ASCO 2026 (May 29-June 2).
Financial Impact
Positive Phase 3 data and Priority Review significantly increase probability of approval and commercial potential for gedatolisib; peak sales potential in HR+/HER2- breast cancer could be multi-billion dollars.
Risk Factors
- Potential for FDA advisory committee concerns or complete response letter despite positive data.
- Competitive landscape: alpelisib, AKT inhibitors, other PI3K/mTOR agents.
- Manufacturing or safety issues that could delay approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286249 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 26, 2026 5w ago | 8-K | $95.08 $84.00 | ▼ −11.65% | ▼ −12.86% | $72.69 (−23.55%) |
Jul 15, 2026 11w ago | 144 | $91.51 $92.08 | ▼ −0.62% | ▲ +1.72% | $72.69 (+20.57%) |
Jul 14, 2026 11w ago | Press Release | $91.51 $92.08 | ▲ +0.62% | ▼ −1.72% | $72.69 (−20.57%) |
Jun 11, 2026 16w ago | Institutional Cluster | $89.49 $113.51 | ▲ +26.84% | ▲ +24.95% | $72.69 (−18.77%) |
Jun 8, 2026 16w ago | 8-K | $92.59 $115.72 | ▲ +24.98% | ▲ +23.53% | $72.69 (−21.49%) |
Jun 5, 2026 17w ago | 424B5 | $88.28 $108.58 | ▲ +23.00% | ▲ +21.13% | $72.69 (−17.66%) |
Jun 4, 2026 17w ago | Press Release | $92.47 $107.95 | ▲ +16.74% | ▲ +18.11% | $72.69 (−21.39%) |
Jun 3, 2026 17w ago | Press Release | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.69 (+18.28%) |
Jun 3, 2026 17w ago | 424B5 | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.69 (+18.28%) |
Jun 2, 2026 17w ago | 8-K | $91.42 $104.49 | ▲ +14.30% | ▲ +15.86% | $72.69 (−20.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access